Journal Article

Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma

Lois B. Travis, Deirdre Hill, Graça M. Dores, Mary Gospodarowicz, Flora E. van Leeuwen, Eric Holowaty, Bengt Glimelius, Michael Andersson, Eero Pukkala, Charles F. Lynch, David Pee, Susan A. Smith, Mars B. Van't Veer, Timo Joensuu, Hans Storm, Marilyn Stovall, John D. Boice, Ethel Gilbert and Mitchell H. Gail

in JNCI: Journal of the National Cancer Institute

Volume 97, issue 19, pages 1428-1437
Published in print October 2005 | ISSN: 0027-8874
Published online October 2005 | e-ISSN: 1460-2105 | DOI:
Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma

Show Summary Details


Background: Many women develop breast cancer after treatment for Hodgkin lymphoma (HL) at a young age. We estimated this future risk, taking into account age and calendar year of HL diagnosis, HL treatment information, population breast cancer incidence rates, and competing causes of death. Methods: Relative risks of breast cancer for categories defined by radiation dose to the chest (0, 20–<40 Gy, or ≥40 Gy) and use of alkylating agents (yes or no) were estimated from a case–control study conducted within an international population-based cohort of 3817 female 1-year survivors of HL diagnosed at age 30 years or younger from January 1, 1965, through December 31, 1994. To compute cumulative absolute risks of breast cancer, we used modified standardized incidence ratios to relate cohort breast cancer risks to those in the general population, enabling application of population-based breast cancer rates, and we allowed for competing risks by using population-based mortality rates in female HL survivors. Results: Cumulative absolute risks of breast cancer increased with age at end of follow-up, time since HL diagnosis, and radiation dose. For an HL survivor who was treated at age 25 years with a chest radiation dose of at least 40 Gy without alkylating agents, estimated cumulative absolute risks of breast cancer by age 35, 45, and 55 years were 1.4% (95% confidence interval [CI] = 0.9% to 2.1%), 11.1% (95% CI = 7.4% to 16.3%), and 29.0% (95% CI = 20.2% to 40.1%), respectively. Cumulative absolute risks were lower in women treated with alkylating agents. Conclusions: Breast cancer projections varied considerably by type of HL therapy, time since HL diagnosis, and age at end of follow-up. These estimates are applicable to HL survivors treated with regimens of the past and can be used to counsel such patients and plan management and preventive strategies. Projections should be used with caution, however, in patients treated with more recent approaches, including limited-field radiotherapy and/or ovary-sparing chemotherapy.

Journal Article.  9038 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.